ATNX Athenex Inc.

15.4
+0.58  (+4%)
Previous Close 14.82
Open 15.16
Price To Book 6.67
Market Cap 1,190,316,589
Shares 77,293,285
Volume 640,577
Short Ratio
Av. Daily Volume 799,782

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 preliminary data showed 50% PR and 50% SD among first 12 patients.
Oraxol
Breast cancer
Phase 1b data noted 2/6 and 3/6 PRs in first two cohorts.
Oraxol and CYRAMZA (Ramucirumab)
Gastric cancer
NDA filing due 1Q 2019.
tirbanibulin ointment
Actinic keratosis
Phase 3 top-line data met primary endpoint (ORR), secondary endpoints (PFS/OS) yet to hit.
Oraxol
Metastatic breast cancer
Clinical trials to commence 2019.
Oral Eribulin
Phase 1/2 initiation announced November 26, 2018.
Oraxol and pembrolizumab (Keytruda)
Solid Tumors
Phase 1 poster at ASCO June 1, 2019.
Oratecan (ASCO 2019)
Solid Tumors
Phase 1 preliminary data released May 3, 2019. 3/7 complete responses.
Oraxol
Angiosarcoma

Latest News

  1. Analyst: Athenex drug trial results showcased 'significant commercial potential'
  2. Edited Transcript of ATNX earnings conference call or presentation 7-Aug-19 12:00pm GMT
  3. Athenex, Inc. (ATNX) Q2 2019 Earnings Call Transcript
  4. Why This Highflying Biotech With A 50% Gain For 2019 Just Crashed
  5. Phase III results are in for Athenex's leading drug candidate, but reaction is varied
  6. Athenex (ATNX) Reports Q2 Loss, Tops Revenue Estimates
  7. Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance
  8. Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer
  9. Do Insiders Own Shares In Athenex, Inc. (NASDAQ:ATNX)?
  10. Athenex Provides an Update Regarding the Vasopressin Case
  11. Will Athenex (ATNX) Report Negative Earnings Next Week? What You Should Know
  12. Athenex, Inc. to Report Second Quarter 2019 Earnings Results on August 7, 2019
  13. Athenex (ATNX) in Focus: Stock Moves 6.5% Higher
  14. Athenex Announces Strategic Global Initiatives to Expand Clinical Operations
  15. SunGen Pharma Announces to Partner with Athenex Pharmaceutical to Launch Bivalirudin through PIV Challenges in US
  16. Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)
  17. A Biotech Pro Loaded Up on These 2 Stocks
  18. Athenex Rallies on Positive Early Data on Psoriasis Candidate
  19. Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
  20. Athenex Provides an Update on its Chongqing API Plant